Myocardial metabolic background on chemotherapy and means of their correction

Recent years have seen significant progress in the treatment of many oncologicaldiseases associated with the development of new chemotherapeutic agents. Typically, they are used in combination with classical chemotherapy regimens that in-clude doxorubicin. In the background of this combined treatment significant prolongation of life of the patients was noted, but at the same time the risk of cardiotoxicity was considerably increased. The survey provides information about the cardiomyocytesmetabolic disorders during therapy with anthracyclines, discussing the possibility of pathogenetic treatment and prevention.